[Featured Stock] DND Pharmatech Advances Follow-up Research on 'GLP-1' Parkinson's Disease Treatment... 'Strong Performance'

DND Pharmatech is showing strong performance. It appears that news of its subsidiary Neuraly conducting follow-up clinical research on Parkinson's disease treatment has had an impact.

As of 10:42 AM on the 12th, DND Pharmatech was trading at 34,750 KRW, up 1,800 KRW (5.46%) from the previous trading day.

On this day, DND Pharmatech announced that its subsidiary Neuraly is collaborating with the National Institute on Aging (NIA) under the U.S. National Institutes of Health (NIH) and Johns Hopkins University School of Medicine to conduct biomarker research and development (R&D) using serum samples from patients who participated in the Phase 2 clinical trial of NLY01 for Parkinson's disease.

This project involves joint research participation by Johns Hopkins University School of Medicine and the National Institute on Aging along with Neuraly researchers. At Johns Hopkins, the project will be led by Professor Ted Dawson, a world-renowned expert in degenerative brain diseases. At NIA, Dr. Dimitrios Kapogiannis, head of the neuroscience division and developer of a method for isolating brain cell-derived extracellular vesicles (EV) from blood, will be a key researcher.

The goal is to use serum samples from patients who participated in the NLY01 Phase 2 clinical trial to identify brain inflammation and Parkinson's disease-related biomarkers by utilizing EVs secreted from the brain. The aim is to discover biomarkers that can distinguish between patients who showed therapeutic effects from NLY01 and those who did not.

Through this, the therapeutic effect of NLY01 can be precisely evaluated, and ultimately, the development of early diagnostic biomarkers for Parkinson's disease applicable in clinical settings is the ultimate goal. DND Pharmatech will provide serum samples from patients who participated in the NLY01 Parkinson's disease Phase 2 trial without incurring additional costs.

Meanwhile, NLY01 from DND Pharmatech is a long-acting GLP-1 class new drug under development targeting degenerative brain diseases including Parkinson's disease. It completed a global Phase 2 clinical trial on Parkinson's disease patients last year.

Significant therapeutic effects were confirmed in younger Parkinson's patients under the age of 60. Currently, the Cure Parkinson Trust in the UK is analyzing multiple GLP-1 clinical results, including NLY01, regarding the excellent therapeutic effects of GLP-1 class drugs in younger Parkinson's patients.